The Better, Harder, Faster, Stronger Study

Summary

The purpose of this study is to evaluate changes in the electronic Frailty Index (eFI) score following 3-4 cycles of neoadjuvant chemotherapy (NACT) in participants with advanced ovarian and endometrial cancer.

Eligibility

Inclusion Criteria:

* Ability to understand and willingness to sign an IRB-approved informed consent.
* Age \> 55 years at the time of enrollment.
* Newly diagnosed suspected ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype, FIGO Stage II-IV, per enrolling investigator, or newly diagnosed suspected endometrial carcinoma of any histologic subtype, FIGO Stage II-IV, per enrolling investigator.
* Planned for 3 or 4 cycles of NACT, with interval cytoreductive surgery planned thereafter.
* Ability to read, understand, and write the English language.
* As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study.

Exclusion Criteria:

* History of brain metastases.
* History of poorly controlled psychiatric conditions, defined as hospitalization within the prior 3 months for psychiatric disorders, traumatic brain injury, cerebrovascular event, or dementia, per the enrolling investigator.
* Use of anti-amyloid agents, cholinesterase inhibitors, or glutamate regulators at the time of enrollment.
* Vision impairment that would impede completion of study assessments, per enrolling investigator.

Conditions6

Locations1 site

Browse More Trials